HVAD to Heartmate 3 Device Exchange: A Society of Thoracic Surgeons Intermacs Analysis

Article Cardiac & Cardiovascular Systems

Concordance of Treatment Effect: An Analysis of The Society of Thoracic Surgeons Intermacs Database

Francis D. Pagani et al.

Summary: This study compared survival rates of contemporary left ventricular assist device technologies using real-world data and various analytic approaches. The results supported the superiority of CF-FML over CF-HL in terms of 1-year survival, validating previous observations made by the STS Intermacs Registry.

ANNALS OF THORACIC SURGERY (2022)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

To P or not to P, that is the question: Four expert opinions on the P value controversy

Eugene H. Blackstone

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices - The CLEAR-LVAD studyTagedEnd

Francis D. Pagani et al.

Summary: An analysis of real-world data on durable LVADs showed that the HeartMate 3 had superior survival rates, lower healthcare resource utilization, and reduced healthcare expenditures compared to other contemporary commercially available LVADs.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cerebrovascular Events in Patients With Centrifugal-Flow Left Ventricular Assist Devices: Propensity Score–Matched Analysis From the Intermacs Registry

Sung-Min Cho et al.

CIRCULATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial

Mandeep R. Mehra et al.

Summary: Over the years, LVAD technology has evolved, with the HM3 LVAD demonstrating superior hemocompatibility compared to the older HMII pump. Experience with the HM3 LVAD has shown nearly eliminated pump thrombosis, significantly reduced stroke rates, and only a modest decrease in bleeding complications. This has led to the questioning of the necessity of antiplatelet therapy in reducing bleeding events for patients implanted with LVADs.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems